I. MODIFIED AGREEMENTS

Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Change from original agreement

Terms/Details (Date)

Lynx Therapeutics Inc. (LYNX)

Takara Bio Inc. (Japan)

Amended technology licensing agreement

Takara made a payment of $3M in order to be relieved of its obligation to make tech- nology access fee payments to Lynx totaling about $2M; it also was cleared of royalty payments; Takara also will acquire three additional Massively Parallel Signature Sequencing instruments; Takara will no longer be required to make future equity investments in Lynx (8/5)

Meditech Pharmaceuticals (OTC BB:MDCH)

Elan Group Ltd. (division of Elan Corp. plc; Ireland)

Extended joint venture that is pursuing equity and potential strategic alliances  to market its solutions to bioterrorism

The term is extended until Dec. 5, 2003 (8/22)

Memory Pharmaceuticals Inc.*

F. Hoffmann-La Roche Ltd. (Switzerland)

Expanded collaboration to include new target

Deal is worth up to $150 million to Memory plus royalties, the same amount as original deal; initial products are in schizophrenia and Alzheimer's, with Memory having R&D control through Phase IIa and Roche funding the work; Roche has worldwide option on products and Memory has co-promotion option (9/18)

Micrologix Biotech Inc. (Canada; TSE:MBI)

Fujisawa Healthcare Inc.

Agreement to extend review period to Jan. 22, 2004

The extension allows more time for evaluation of options following analysis of MBI 226 Phase III data, which were negative (9/22)

Perlegen Sciences Inc.*

Eli Lilly and Co.

Expanded research collaboration under which Perlegen genotypes SNPs in samples to identify genetic markers

Lilly will increase its research funding to support the expanded work, in addition to paying undisclosed milestones and royalties that were part of the original deal (9/23)

Pharmacopeia Inc. (PCOP)

Schering-Plough Corp.

Extended agreement for three years for the companies to work to identify candidates  for Schering-Plough to develop based on the creation of combinatorial libraries created in the earlier part of the deal

Pharmacopeia will receive research funding and would receive other payments as milestones are reached (9/5)

Quark Biotech Inc.*

Fujisawa Pharmaceutical Co. Ltd. (Japan)

Extended research collaboration for target discovery and drug development for stroke

Quark and Fujisawa will continue their validation program on candidate genes and/or proteins selected for further research and the construction of bioassays for screening small-molecule drug libraries (8/6)

Scynexis Inc.*

F. Hoffmann-La Roche Ltd. (Switzerland)

Broadened and extended research agreement to discover and develop compounds for central nervous system and metabolic diseases

Roche gains access to the Scynexis MedChem-Factory technology and HEOS Hit Explorer Operating System software; Roche will receive exclusive worldwide rights to products developed through the collaboration in exchange for technology access fees and other compensation for Scynexis technologies and services (9/12)

Structural GenomiX Inc.*

Boehringer Ingelheim GmbH (Germany)

Expanded two-year agreement to allow Boehringer to use the SGX synchrotron beamline facility

SGX will generate crystal structure data on Boehringer drug targets and compounds to enable Boehringer to integrate co-crystal structural information into its process (9/23)

Tripos Inc. (TRPS)

Bristol-Myers Squibb Co.

Extended agreement to integrate Tripos' FormBuilder technology into BMS' Smart-Idea application

The technology is expected to be deployed in 2004; the original collaboration began in 2002 (9/24)

II. TERMINATED AGREEMENTS

Atrix Laboratories Inc. (ATRX)

Elan Corp. plc (Ireland)

Terminated joint venture focused on the development of pain management products

Atrix regains rights to the BEMA-fentanyl product for breakthrough cancer pain; Atrix is acquiring Elan's ownership interest in the venture in exchange for Elan receiving a portion of any consideration Atrix receives from the licensing of BEMA-fentanyl and a royalty if the product is commercialized (9/16)

Cell Genesys Inc. (CEGE)

Japan Tobacco Inc. (Japan)

Terminated agreement for GVAX cancer vaccines

he agreement was terminated in October 2002, but the companies agreed on wind-down payments of $8.3M in cash to Cell Genesys and the waiver of $8.5M in future repayment obligations (8/28)

Emisphere Technologies Inc. (EMIS)

Eli Lilly and Co.

Terminated agreement for an oral recombinant human growth hormone program, which employed Emisphere's eligen delivery technology

Lilly is discontinuing its support of the program in an effort to prioritize products in its pipeline (8/12)

NiCox SA (France; NICXF)

AstraZeneca plc (US)

Terminated agreement on class of anti-inflammatory and analgesic compounds called  CINODs

Alliance was ended after AstraZeneca decided not to move AZD 3582 into Phase III studies (9/23)

Karo Bio AB (Sweden; SSE:KARO)

Merck & Co. Inc.

Terminated agreement for the first of two candidate compounds in a collaboration between the companies

Development was discontinued with the first compound due to adverse findings in the final stages of preclinical testing; the companies continue to study the second compound and other estrogen receptor compounds that came out of the November 1997 collaboration (8/19)

Millennium Pharmaceuticals Inc. (MLNM)

Abbott Laboratories

Terminated collaboration for research in the metabolic disease area

Millennium terminated the agreement in order to narrow its focus and shift resources (8/14)

Phytopharm plc (UK; LSE:PYM)

Pfizer Inc.

Terminated development agreement for P57, an obesity treatment

Pfizer dropped development of Phytopharm's P57 following its acquisition of Pharmacia Corp. (8/6**)

Transkaryotic Therapies Inc. (TKTX)

Wyeth Pharmaceuticals therapy platform

Terminated agreement for a Factor VIII gene

TKT regains European rights and received a $500,000 termination fee (8/11)

Notes:

^# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange.